カテゴリ： GlobalData, アメリカ, 企業調査

National Comprehensive Cancer Network：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：National Comprehensive Cancer Network - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9314
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：63
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
National Comprehensive Cancer Network (NCCN) is a not-for-profit cancer center that offers patient care, research, and education services. The center offers research and medical information to help patients and health professionals related to cancer care. It provides subscriptions and products which include NCCN flash updates, NCCN drugs and biologic compendium, NCCN chemotherapy order templates, NCCN trends and NCCN academy video modules, among others. NCCN also offers accredited educational opportunities and tools; conferences and congresses. The center’s research areas include oncology pre clinical, translation and clinical research. It caters its services to patients, clinicians and health care decision-makers. NCCN is headquartered in Philadelphia, Pennsylvania, the US.

National Comprehensive Cancer Network – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 18
Bristol-Myers Squibb Enters into Research Agreement with NCCN 19
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 20
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute Form Joint Venture 21
Juno Therapeutics Enters into Research Agreement with FHCRC 22
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 23
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 24
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 25
Licensing Agreements 27
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 27
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 28
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 29
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 31
Juno Therapeutics Enters into Licensing Agreement with FHCRC 32
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 33
National Comprehensive Cancer Network – Key Competitors 35
National Comprehensive Cancer Network – Key Employees 36
National Comprehensive Cancer Network – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Government and Public Interest 39
Sep 11, 2018: New Guidelines Provide Vital Information for Women Diagnosed with the Most Common Type of Gynecologic Cancer 39
Aug 09, 2018: NCCN publishes first-ever U.S. guidelines for rare cancers associated with pregnancy 40
Jul 23, 2018: New Study in JNCCN Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40 41
Apr 26, 2018: New Translations of NCCN Guidelines for Patients Advance Global Mission to Empower People with Cancer 42
Apr 18, 2018: New Study Shows Why Cancer Cost Planning Needs to Start Accounting for People Under 65 43
Apr 04, 2018: NCCN Helps Strengthen Cancer Research Pipeline by Awarding Grants to Five Young Investigators 44
Mar 29, 2018: National Comprehensive Cancer Network Honors Key Contributors to the Improvement of Global Cancer Care and Dedication to the NCCN Mission 45
Mar 13, 2018: Testicular Cancer Survivors Need Adequate Screening for Long Term Heart Disease Risks 46
Feb 27, 2018: New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes 47
Jan 31, 2018: NCCN Reaches New Records for Guidelines, Resources, and Programs 49
Jan 25, 2018: NCCN Imaging Appropriate Use Criteria Endorsed by Intermountain Healthcare and Will be Included in the Intermountain AUC for Lung Cancer 50
Jan 22, 2018: Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer 51
Dec 01, 2017: Advocates Reveal Cancer Survivorship Challenges and Resources during National Comprehensive Cancer Network’s Patient Advocacy Summit 52
Nov 29, 2017: National Comprehensive Cancer Network Introduces New Guidelines for Patients with a Form of Cancer Associated with HIV and AIDS 53
Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 54
Sep 27, 2017: Study Finds “Standard Care” Treatments in Breast Cancer Clinical Trials Not Always Standard 55
Aug 11, 2017: New NCCN Patient Resources for Rectal Cancer Now Available 56
May 19, 2017: NCCN and Pfizer Address Quality Improvement in Breast Cancer through Clinical Pathways 57
Other Significant Developments 58
Sep 17, 2018: New Benchmarking Tool for Measuring Development and Organization of Integrated Practice Units Published in Journal of the National Comprehensive Cancer Network 58
Jun 21, 2018: New Study in JNCCN Raises Questions about Resource Availability at Hospitals on Weekends and Holidays 59
May 14, 2018: New Tool Helps People with Leukemia Better Understand Their Treatment Options 60
Apr 10, 2018: NCCN Provides New, Free Database to Assist in Cancer Research Collaborations 61
Mar 28, 2018: Nearly Two Thousand Cancer Experts Come Together to Discuss Ways to Improve Quality, Effectiveness, and Efficiency of Care 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Key Facts 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 14
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 15
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 16
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 17
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 18
Bristol-Myers Squibb Enters into Research Agreement with NCCN 19
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 20
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 21
Juno Therapeutics Enters into Research Agreement with FHCRC 22
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 23
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 24
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 25
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 27
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 28
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 29
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Rocket Pharma Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 31
Juno Therapeutics Enters into Licensing Agreement with FHCRC 32
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 33
National Comprehensive Cancer Network, Key Competitors 35
National Comprehensive Cancer Network, Key Employees 36
National Comprehensive Cancer Network, Subsidiaries 38

List of Figures
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Comprehensive Cancer Network, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[National Comprehensive Cancer Network：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Vertex Pharmaceuticals Incorporated：企業の戦略・SWOT・財務情報
    Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • HUP-Zagreb d.d.：企業の戦略・SWOT・財務情報
    HUP-Zagreb d.d. - Strategy, SWOT and Corporate Finance Report Summary HUP-Zagreb d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Colt Group Ltd：企業の戦略的SWOT分析
    Colt Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Antero Resources Corp (AR)：企業の財務・戦略的SWOT分析
    Antero Resources Corp (AR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Zeta Petroleum Plc (ZTA)：企業の財務・戦略的SWOT分析
    Summary Zeta Petroleum Plc (Zeta) is an oil and gas exploration and production company. The company explores, develops and produces natural gas and crude oil. It owns and operates oil and gas assets such as Bobocu Gas Field, Suceava Concession, Jimbolia Oil Field, and Grivita Nord Oil Field. Zeta’s …
  • Oaktree Capital Group Llc：企業の戦略・SWOT・財務分析
    Oaktree Capital Group Llc - Strategy, SWOT and Corporate Finance Report Summary Oaktree Capital Group Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Infosys Limited：戦略・SWOT・企業財務分析
    Infosys Limited - Strategy, SWOT and Corporate Finance Report Summary Infosys Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Allied Hotel Properties Inc：企業の戦略・SWOT・財務情報
    Allied Hotel Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Allied Hotel Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Egdon Resources Plc (EDR)：企業の財務・戦略的SWOT分析
    Summary Egdon Resources Plc (Egdon) is oil and gas company that offers exploration and production services. The company explores and develops petroleum and natural gas assets in East Midlands, North East England, North West England, and Southern England, the UK. Its project site includes Wressle, No …
  • STMicroelectronics N.V. (STM)-エネルギー分野：企業M&A・提携分析
    Summary STMicroelectronics N.V. (ST) is a microelectronics company that designs, develops, manufactures, and markets a broad range of products for analog, digital, and mixed-signal applications. It offers standard commodity components, custom devices and semi-custom devices, application-specific int …
  • Martindale Pharmaceuticals Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Martindale Pharmaceuticals Ltd (Martindale), a subsidiary of Cardinal Health Inc is a pharmaceutical company that offers formulations. The company provides hospital-initiated medicines in emergency medicine and differentiated products in complex neurological conditions,opioid addiction and p …
  • Avista Corporation (AVA)-エネルギー分野：企業M&A・提携分析
    Summary Avista Corporation (Avista) is an electric and natural gas utility. The company produces, transmits, and distributes electricity; and supplies natural gas on retail and wholesale basis. It sources electricity from its facilities and contracted hydroelectric, thermal and wind generation facil …
  • Alucon Public Company Limited：戦略・SWOT・企業財務分析
    Alucon Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Alucon Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • PVA TePla AG (TPE)：企業の財務・戦略的SWOT分析
    PVA TePla AG (TPE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Life Healthcare Group Holdings Ltd (LHC)：企業の財務・戦略的SWOT分析
    Life Healthcare Group Holdings Ltd (LHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Kwality Group：企業の戦略・SWOT・財務分析
    Kwality Group - Strategy, SWOT and Corporate Finance Report Summary Kwality Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Vertex Pharmaceuticals Incorporated：企業の戦略・SWOT・財務分析
    Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Precipio Inc (TBIO)：医療機器：M&Aディール及び事業提携情報
    Summary Precipio Inc (Precipio), formerly Transgenomic Inc, is a developer and provider of diagnostic tools and services. The company advances personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services …
  • Tenaga Nasional Bhd (TENAGA)：電力：M&Aディール及び事業提携情報
    Summary Tenaga Nasional Bhd (TNB) is an electricity utility that generates, transmits, distributes and supplies power. It develops, operates and maintains a portfolio of power generating units. The company produces electricity from crude oil, natural gas, hydro, coal and gas sources. TNB also suppli …
  • GSI Creos Corporation：企業の戦略・SWOT・財務情報
    GSI Creos Corporation - Strategy, SWOT and Corporate Finance Report Summary GSI Creos Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆